Aquestive Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Aquestive Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2019 to Q3 2024.
  • Aquestive Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -285 %, a 85.6% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -285 -132 -85.6% Sep 30, 2024
Q2 2024 -229 -78.1 -51.6% Jun 30, 2024
Q1 2024 -186 -33.7 -22.1% Mar 31, 2024
Q4 2023 -155 -1.97 -1.29% Dec 31, 2023
Q3 2023 -154 +6.05 +3.79% Sep 30, 2023
Q2 2023 -151 +21 +12.2% Jun 30, 2023
Q1 2023 -152 +34.2 +18.3% Mar 31, 2023
Q4 2022 -153 +49.9 +24.6% Dec 31, 2022
Q3 2022 -160 +60.1 +27.3% Sep 30, 2022
Q2 2022 -172 +54.7 +24.1% Jun 30, 2022
Q1 2022 -187 +64.3 +25.6% Mar 31, 2022
Q4 2021 -203 +86.4 +29.8% Dec 31, 2021
Q3 2021 -220 +183 +45.4% Sep 30, 2021
Q2 2021 -227 +181 +44.4% Jun 30, 2021
Q1 2021 -251 +130 +34.2% Mar 31, 2021
Q4 2020 -290 +155 +34.8% Dec 31, 2020
Q3 2020 -403 +158 +28.2% Sep 30, 2020
Q2 2020 -408 -10.8K -104% Jun 30, 2020
Q1 2020 -381 +2.2K +85.2% Mar 31, 2020
Q4 2019 -445 Dec 31, 2019
Q3 2019 -561 Sep 30, 2019
Q2 2019 10.4K Jun 30, 2019
Q1 2019 -2.58K Mar 31, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.